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updated and may offer a stronger message compared with previous meta-analyses with respect to clinical impact of IPC. A second positive aspect of this meta-analysis is that authors assessed the association of IPC with hard clinical outcomes including all-cause and cardiac mortality and not intermediary (surrogate) endpoints. The inclusion of randomized trials only represents another strength of current meta-analysis. Finally, to my knowledge, the meta-analysis is performed according guideline criteria on meta-analyses and the used methodology is appropriate. Notwithstanding these merits, the meta-analysis has limitations which are addressable: 1. The authors have to state that this meta-analysis included only local and not remote IPC. There are differences in putative mechanisms or efficacy (at least based on existing ttrials) between these IPC modalities. 2. Although searching criteria are similar, the number of included studies differs across various meta-analyses (the current metaanalysis has a smaller number of randomized trials compared with previous ones even though it is most recent). The authors accepted that: "Although, we performed an extensive search strategy, some studies might not be included in this metaanalysis." This is unacceptable, at least, to this reviewer. The authors should make every effort needed to collect all studies fulfilling the search criteria. This is crucial for meta-analyses. 3. There are several technical deficiencies throughout the material. Thus the forest plot for MACE has not been shown even though MACE was defined as a (co)primary outcome (figure 2 represents forest plots for individual components but not for MACE as a composite end point). Heading for figure 1 is missing. The name of the journals for references 18-20 is missing. I found no legend for figure on page 22. 4. The quality of English is problematic, particularly for the discussion section of the manuscript.
REVIEWER
Thomas Engstrøm Rigshospitalet, University of Copenhagen, Denmark REVIEW RETURNED 19-Mar-2018
GENERAL COMMENTS
Xing et al. investigated in a metanalysis the effect of ischemic postconditioning (iPOST) in patients with STEMI. They found in 9 STEMI trials that all-cause mortality was not affected by iPOST, neither was a number of secondary endpoints. The metanalysis was performed on the basis on published randomised trials -not on individual patient data. Although iPOST is interesting per se in STEMI patients the paper has a number of major limitations.
1. The DANAMI3-iPOST constitutes more than one third of the study population, and therefore, although accounted for in the methodology, skewness of data may have occurred.
2. The effect on any conditioning technique is supposed to reduce myocardial damage after ischemia and reperfusion. Thus, the concept relies on the fact that reperfusion may itself damage the myocardium on top of the ischemic insult (coronary occlusion). Therefore, heart failure after STEMI treatment and subsequent death is the relevant outcome targets. It does therefore, seem inappropriate to examine the effect of iPOST on subsequent myocardial infarction and revascularisation. In addition, it is unclear what is the true primary endpoint. As written in the method section all-cause mortality and MACE is the primary endpoint (coprimary?).
3. The adjuvant medical treatment in the trials included was not uniform. Thus, in some trials clopidogrel was used and in others the newer P2Y12 inhibitors prasugrel and ticagrelor of which the latter may itself act as a conditioning agent. In addition, the use of bivalirudin and GP IIB/IIIA inhibitors and thrombectomy, which may affect peripheral embolization and subsequent myocardial damage, was different between studies and inconsistently reported.
4. Follow-up periods are very different between studies (ranging from 1 month to more than 3 years). Since congestive heart failure is fatal over a longer period of time (50% within 5 years) and iPOST is supposed to reduce myocardial damage (and thus the occurrence of heart failure) no mortality reduction can reasonably be expected very early.
5. The primary endpoint of all-cause mortality occurs in general between 3-10% after one year in a STEMI population. If done in a randomised fashion a reduction from 10% to 8% would require 6000 patients to be well powered. Thus, although being a metanalysis and in some of the studies follow is longer there is considerable risk that the analysis is underpowered. Numbers do not agree with Table 1 Tarantini 37/38 in Table 1 but 39/39 in Figure 1 Luz 43/43 in Table 1 but 50/50 in Figure 1 Label -Ischaemic post conditioning to be consistent Figure 2 Not ordered by year of study What are the numbers before , e.g. heart failure? Labelled "favours experimental" different to Figure 1 Supp and how to perform ischemic postconditioning in the section of background. Your suggestion makes it easy for the viewer or reader to understand our study. 2. In order to include all relevant RCTs, we manually searched the reference lists of relevant studies and reviews, editorials, and letters again to identify further articles, especially relevant meta-analysis. We found one RCT new. We added it to our analyses. Most RCTs or metaanalyses regarding this topic (local ischemic conditioning) focused on LVEF, CK-MB, TNT, or TNI. Different from previous meta-analyses, we focused on hard clinical endpoints. We had to exclude these studies because of inaccessibility of relevant data. 3. Thanks for your reminding. I am sorry for my mistakes. We have corrected these technical deficiencies. Thanks a lot. MACE was showed at the bottom of forest plot(fig2). MACE included cardiac death, heart failure, myocardial infarction(MI). All individual component summarized into MACE. We added heading for figure 1 and the name of the journals for references 18-20. 4. We improved our language.
REVIEWER
Response to Reviewer: 2 I appreciated your hard work in this field. You performed the largest RCT regarding ischemic postconditioning which deepened our understanding of ischemic postconditioning. 1. Although DANAMI3-iPOST constitutes more than one third of the study population, our conclusion is still unchanged if we exclude this largest RCT. Sensitivity analyses and subgroup analyses have shown that no RCT influences the direction of the overall effects (both primary endpoint and second endpoint). 2. Thanks for your profound opinion. We have realized that it is inappropriate to examine the effect of iPOST on myocardial infarction and revascularization. Therefore，we changed our study endpoints according to your suggestion. Our primary outcome is heart failure, second endpoint is all-cause mortality, and MACE (heart failure, myocardial infarction, cardiac death). 3. I appreciate your kind reminding. heterogeneities between studies is inevitable. Most studies used clopidogrel rather than the newer P2Y12 inhibitors prasugrel and ticagrelor. Eitel 2015 used the newer P2Y12 inhibitors (32%). 6 of 10 studies used GPIIb/IIIa inhibitors. 4 of 10 used bivalirudin (Table 1 ) Therefore, subgroup analyses were performed. Subgroup analysis showed that these heterogeneities did not influence our results (Table 2 ). 4. We performed subgroup analyses according to different follow-up periods. However, we did not find that iPOST could reduce the rate of congestive heart failure. However, this is the largest meta-analyses, more clinical trials, such as DANAMI3-iPOST, is needed. Can you share 5-year outcomes of DANAMI3-iPOST with us in the near future? 5. I agree with you, but with some reservation. The number of all-cause mortality between groups is almost same. We performed trial sequential analysis(TSA). TSA can estimate sample size needed, provide incentives for new high-quality trials, and may stop further trials if the intervention benefits are remote or nonexistent or when the intervention effect is dramatic and no more trials are needed. the result demonstrated that iPOST did not reduce all-cause mortality regardless of limited simple size. We have estimated the simple size of all-cause mortality and heart failure(α=0.05, 1-β=80%).
All-cause mortality: The Z-curve dose not cross the traditional line(p=0.05) and trial sequential boundary but crosses the futility line which indicates the intervention benefits are remote or nonexistent
Heart failure: The Z-curve does not cross the traditional line(p=0.05) and trial sequential boundary but crosses the futility line which indicates the intervention benefits are remote or nonexistent
Response to Reviewer: 3 I appreciate your kind suggestions and your thoughtful comments. 1
We have improved our language. 2
We have re-upload figures and supplementary figures with at least 300 dpi resolution 3
We have included a statement of "patient and public involvement" in the contributorship statement/acknowledgements. 4 a.b.c. this is a meta-analysis of RCTs rather than RCT. Therefore, no patient involves in the design of this study. As a result, patents did not need to know the development of our research question and outcomes. Furthermore, These RCTs were not performed by us. As a result, we were unable to inform patients our research question and outcomes. We searched relevant studies regarding ischemic postconditioning. The objective of this study is to give a relatively objective conclusion that whether ischemic postconditioning can improve hard clinical endpoint. d. This strategy, known as ischemic postconditioning, is safe, easy to preform without additional cost. As a result, this strategy did not increase the burden of patients. All included studies have stated that patients or guardians have signed the informed consent form. Furthermore, our study is a meta-analysis rather than a RCT. we study did not include intervention therapies and patients' information. No ethical review or informed consent is required. e. We have thanked the patient advisers in the contributorship statement/acknowledgements. f. We have stated that patents or public were not involved in the contributorship statement/acknowledgements.
VERSION 2 -REVIEW

REVIEWER
Gjin Ndrepepa
German Heart Center Munich, Technical University, Munich, Germany REVIEW RETURNED 18-Jun-2018
GENERAL COMMENTS
The authors have responded to all raised questions.
REVIEWER
Thomas Engstrøm Rigshospitalet University of Copenhagen, Denmark REVIEW RETURNED
04-Jul-2018
GENERAL COMMENTS
Xing et al. investigated in a metanalysis the effect of ischemic postconditioning (iPOST) in patients with STEMI. They found in 10 STEMI trials (3137 patients) that heart failure was not affected by iPOST, neither was a number of secondary endpoints. The metanalysis was performed on the basis on published randomised trials -not on individual patient data. The manuscript is much more focused than the previous one. It does need substantial revision of the language.
Specific points:
1. Why is data for heart failure with regard to the primary endpoint 0.88 (95% CI: 0.61-1.26, P= 148 0.47) and thus different from data for heart failure with regard to MACE (RR: 0.85, 95% CI: 0.59,1.23, P = 0.40).
2. The adjuvant medical treatment in the trials included was not uniform. Thus, in some trials clopidogrel was used and in others the newer P2Y12 inhibitors prasugrel and ticagrelor of which the latter may itself act as a conditioning agent. In addition, the use of bivalirudin and GP IIB/IIIA inhibitors and thrombectomy, which may affect peripheral embolization and subsequent myocardial damage, was different between studies and inconsistently reported.
3. Follow-up periods are very different between studies (ranging from 1 month to more than 3 years). Since congestive heart failure is fatal over a longer period of time (50% within 5 years) and iPOST is supposed to reduce myocardial damage (and thus the occurrence of heart failure) no mortality reduction can reasonably be expected very early.
4. The primary endpoint of heart failure occurs in less than 5% after one year in a STEMI population. Thus, although being a metanalysis and in some of the studies follow up is longer there is considerable risk that the analysis is underpowered with 3000 patients. Thus the metanalysis probably does not answer the question asked. 2. We have performed subgroup analyses regarding newer P2Y12 inhibitors prasugrel and ticagrelor or GP IIB/IIIA inhibitors. We did not find a different results. Most studies did not reported the incidence of thrombectomy.
VERSION 2 -AUTHOR RESPONSE
3. Subgroup analysis was performed depending on different follow-up time, we did not find a different result. Whether iPOST is effective in reducing myocardial damage is still in debate. (Heart 2010; 96:1710e1715, Circulation. 2013 128:1889 -1896 . there is no consensus. although the concept of iPOST have been come forward nearly two decades, the relevant STEMI guideline did not make any recommendation.
4. We have to admit that the simple size is not enough, we will discuss it in the section of Limitation . However, this study included nearly all relevant studies, more relevant studies are needed in the future. we just expect to throw out a brick to attract a jade. Furthermore, the debate on iPOST, which have been lasted for decades, can not be solved by our study.
5. We have improved our language.
Response to reviewer #3 Line Comment Our response'/ 58 Expand IPC for the first time in main report.
We have expand IPC for the first time in main report 108-118 How did you deal with studies that have no events hence the RR cannot be calculated?
No mention of meta-regression, subgroups analyses or sensitivity analyses
The software usually delete this study in calculating the pooled RR
We have mentioned sub-groups analyses or sensitivity analyses in the section of method and deleted meta-regression in the section of results
115
What do you mean that "data analysis will be done on an intention to treat basis"? Does this refer to the trials identified?
An intention-to-treat (ITT) analysis of the results of an experiment is based on the initial treatment assignment and not on the treatment eventually received. ITT analysis is intended to avoid various misleading artifacts that can arise in intervention research such as non-random attrition of participants from the study or crossover.
We identified clinical endpoints on an intention to treat basis Numbers do not agree with Table 1 Tarantini 37/38 in Table 1 but 39/39 in Figure 1 Luz 43/43 in Table 1 but 50/50 in Figure  1 Label -Ischaemic post conditioning to be consistent
We have corrected in the revised manuscript Figure 2 Not ordered by year of study What are the numbers before , e.g. heart failure?
Labelled "favours experimental" different to Figure 1 We have corrected these mistakes Supp 
